285 related articles for article (PubMed ID: 29262808)
1. Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.
Damodaran S; Damaschke N; Gawdzik J; Yang B; Shi C; Allen GO; Huang W; Denu J; Jarrard D
BMC Cancer; 2017 Dec; 17(1):874. PubMed ID: 29262808
[TBL] [Abstract][Full Text] [Related]
2. Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development.
Lee JH; Yang B; Lindahl AJ; Damaschke N; Boersma MD; Huang W; Corey E; Jarrard DF; Denu JM
ACS Chem Biol; 2017 Nov; 12(11):2804-2814. PubMed ID: 28949514
[TBL] [Abstract][Full Text] [Related]
3. Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells.
Filon M; Yang B; Purohit TA; Schehr J; Singh A; Bigarella M; Lewis P; Denu J; Lang J; Jarrard DF
Oncotarget; 2023 Jul; 14():738-746. PubMed ID: 37477521
[TBL] [Abstract][Full Text] [Related]
4. High glucose-induced oxidative stress represses sirtuin deacetylase expression and increases histone acetylation leading to neural tube defects.
Yu J; Wu Y; Yang P
J Neurochem; 2016 May; 137(3):371-83. PubMed ID: 26896748
[TBL] [Abstract][Full Text] [Related]
5. A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection.
Eskandarian HA; Impens F; Nahori MA; Soubigou G; Coppée JY; Cossart P; Hamon MA
Science; 2013 Aug; 341(6145):1238858. PubMed ID: 23908241
[TBL] [Abstract][Full Text] [Related]
6. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.
Bianco-Miotto T; Chiam K; Buchanan G; Jindal S; Day TK; Thomas M; Pickering MA; O'Loughlin MA; Ryan NK; Raymond WA; Horvath LG; Kench JG; Stricker PD; Marshall VR; Sutherland RL; Henshall SM; Gerald WL; Scher HI; Risbridger GP; Clements JA; Butler LM; Tilley WD; Horsfall DJ; Ricciardelli C;
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2611-22. PubMed ID: 20841388
[TBL] [Abstract][Full Text] [Related]
7. Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ.
Hou H; Chen W; Zhao L; Zuo Q; Zhang G; Zhang X; Wang H; Gong H; Li X; Wang M; Wang Y; Li X
J Clin Pathol; 2012 Dec; 65(12):1088-96. PubMed ID: 22944623
[TBL] [Abstract][Full Text] [Related]
8. H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy.
Hałasa M; Wawruszak A; Przybyszewska A; Jaruga A; Guz M; Kałafut J; Stepulak A; Cybulski M
Cells; 2019 May; 8(5):. PubMed ID: 31121824
[TBL] [Abstract][Full Text] [Related]
9. Global histone modification patterns predict risk of prostate cancer recurrence.
Seligson DB; Horvath S; Shi T; Yu H; Tze S; Grunstein M; Kurdistani SK
Nature; 2005 Jun; 435(7046):1262-6. PubMed ID: 15988529
[TBL] [Abstract][Full Text] [Related]
10. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients.
Ellinger J; Schneider AC; Bachmann A; Kristiansen G; Müller SC; Rogenhofer S
Anticancer Res; 2016 Aug; 36(8):3961-4. PubMed ID: 27466500
[TBL] [Abstract][Full Text] [Related]
12. H4K12 and H3K18 Acetylation Associates With Poor Prognosis in Pancreatic Cancer.
Juliano CN; Izetti P; Pereira MP; Dos Santos AP; Bravosi CP; Abujamra AL; Prolla PA; Osvaldt AB; Edelweiss MI
Appl Immunohistochem Mol Morphol; 2016; 24(5):337-44. PubMed ID: 26067135
[TBL] [Abstract][Full Text] [Related]
13. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
14. Global levels of histone modifications predict prostate cancer recurrence.
Ellinger J; Kahl P; von der Gathen J; Rogenhofer S; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Büttner R; Müller SC; Bastian PJ; von Ruecker A
Prostate; 2010 Jan; 70(1):61-9. PubMed ID: 19739128
[TBL] [Abstract][Full Text] [Related]
15. Acetylation of Sirt2 by p300 attenuates its deacetylase activity.
Han Y; Jin YH; Kim YJ; Kang BY; Choi HJ; Kim DW; Yeo CY; Lee KY
Biochem Biophys Res Commun; 2008 Oct; 375(4):576-80. PubMed ID: 18722353
[TBL] [Abstract][Full Text] [Related]
16. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth.
Gang X; Yang Y; Zhong J; Jiang K; Pan Y; Karnes RJ; Zhang J; Xu W; Wang G; Huang H
Oncotarget; 2016 Mar; 7(12):15135-49. PubMed ID: 26934656
[TBL] [Abstract][Full Text] [Related]
17. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
18. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.
Isharwal S; Miller MC; Marlow C; Makarov DV; Partin AW; Veltri RW
Prostate; 2008 Jul; 68(10):1097-104. PubMed ID: 18459105
[TBL] [Abstract][Full Text] [Related]
19. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.
Zucconi BE; Luef B; Xu W; Henry RA; Nodelman IM; Bowman GD; Andrews AJ; Cole PA
Biochemistry; 2016 Jul; 55(27):3727-34. PubMed ID: 27332697
[TBL] [Abstract][Full Text] [Related]
20. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
